Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I

<p>Abstract</p> <p>Background</p> <p>Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (Ph + ALL) are caused by the t(9;22), which fuses <it>BCR</it> to <it>ABL</it> resulting in deregulated AB...

Full description

Bibliographic Details
Main Authors: Mian Afsar, Metodieva Anna, Badura Susanne, Khateb Mamduh, Ruimi Nili, Najajreh Yousef, Ottmann Oliver, Mahajna Jamal, Ruthardt Martin
Format: Article
Language:English
Published: BMC 2012-09-01
Series:BMC Cancer
Subjects:
Philadelphia chromosome
BCR/ABL
“gatekeeper” mutation T315I
Allosteric inhibition
Abl kinase inhibitors
Molecular therapy
Online Access:http://www.biomedcentral.com/1471-2407/12/411

Internet

http://www.biomedcentral.com/1471-2407/12/411

Similar Items